NEWS & UPDATES

• PRIME designation granted by European Medicines Agency for potential gene therapy treatment
  June 5, 2018
  Today, 5th June, Audentes Therapeutics announced that PRIME status has been granted by the European Medicines Agency for their AT132 product (the […]
• Joint research call with the world renowned Great Ormond Street Hospital Charity, and Sparks
  May 31, 2018
  Great Ormond Street Hospital Charity and Sparks have today opened a National Funding Call for £2M of investment in Child Health Research. We are […]
• Audentes Therapeutics announces continuing positive data from first dose cohort of ASPIRO, a phase 1/2 clinical trial of AT132 in patients with x-link…
  May 16, 2018
  Audentes Therapeutics announced continuing positive interim data from the group of patients receiving the first dose of the gene therapy clinical […]
• Roman’s Weekly Lottery Bonus Ball!
  May 10, 2018
  Sophie and Alan Kennett have thought of an ingenious way to raise regular funds to support their son Roman and their chosen charities. They have set […]
• Audentes Therapeutics announce dosing of three additional patients in gene therapy clinical trial 
  May 9, 2018
  Audentes Therapeutics today announced their first quarter 2018 results. For x-linked myotubular myopathy, they reported that the next 3 patients were […]